Oct 21, 6:15 AM ET
Integra LifeSciences reported third-quarter 2026 revenue of $411.2 million, up 2.3% from the prior year, and GAAP earnings of $0.19 per diluted share versus a loss of $(0.07) a year earlier. The company kept its full-year 2026 guidance consistent with its October 2, 2026 outlook, but expects fourth-quarter reported revenue to decline 0.5% to 5.2%, citing the Cincinnati facility disruption and softer Tissue Reconstruction results.
- Q3 revenue $411.2 million, up 2.3% reported and 2.5% organic; GAAP EPS $0.19 vs. $(0.07), adjusted EPS $0.59 vs. $0.54
- Full-year 2026 revenue guidance $1.634 billion to $1.654 billion; adjusted EPS guidance $2.30 to $2.40, consistent with October 2, 2026 outlook
- Fourth-quarter 2026 adjusted EPS guidance $0.61 to $0.71; reported revenue expected to decline 0.5% to 5.2%
- Completed $2.1 billion debt refinancing on October 19, 2026; Q3 operating cash flow $96.0 million
Read the filing on SEC.gov ↗
Oct 19, 4:20 PM ET
Integra LifeSciences entered a $1.65 billion amended and restated credit agreement and closed a $450 million private offering of 9.500% senior secured notes due 2033, both on October 19, 2026. The company used the proceeds and new borrowings to repay in full its Existing Credit Agreement, which had a $1.3 billion revolver and a $775 million term loan. The filing shows new debt and higher-cost secured borrowing terms, but it does not report earnings or guidance changes.
- Notes: $450 million principal, 9.500% interest, payable semi-annually, maturing November 1, 2033
- Credit agreement: $600 million revolver and $600 million term loan A (five-year), plus $450 million term loan B (seven-year)
- Term Loan B applicable rate is 4.25%; revolver and term loan A initially 3.00%, adjusting to 2.00% to 3.25% after the December 31, 2026 quarter
- Existing $1.3 billion revolver and $775 million term loan were repaid in full with no early termination penalties
Read the filing on SEC.gov ↗
Oct 2, 8:20 AM ET
Integra LifeSciences released preliminary third-quarter 2026 results and lowered its full-year 2026 revenue and adjusted EPS guidance after July flooding at its Cincinnati manufacturing facility. The company says the flood reduced third-quarter revenue by about $7 million and will reduce fourth-quarter revenue by $15 million to $20 million, and it expects insurance to offset a substantial portion of the earnings impact.
- Third-quarter revenue expected at $410 million to $412 million, with adjusted EPS of $0.55 to $0.59; results are unaudited and subject to closing procedures.
- Full-year 2026 revenue outlook lowered to $1.634 billion to $1.654 billion from $1.654 billion to $1.695 billion; adjusted EPS guidance lowered to $2.30 to $2.40 from $2.40 to $2.50.
- Full-year 2026 operating cash flow expected at about $190 million to $200 million, and greater than $85 million in the third quarter.
- Full manufacturing operations at the Cincinnati facility are expected to return during the second quarter of 2027.
Read the filing on SEC.gov ↗
Jul 29, 6:15 AM ET
Integra LifeSciences reported second-quarter 2026 revenue of $418.8 million, up 0.8% on a reported basis, and adjusted earnings of $0.56 per diluted share, up from $0.45. It cut its reported full-year 2026 revenue range to $1.654 billion to $1.695 billion, citing a stronger U.S. dollar, while reaffirming its organic growth and adjusted EPS guidance.
- Q2 2026 GAAP EPS was $0.06, compared with a $(6.31) loss in Q2 2025, which included a $511.4 million goodwill impairment charge
- Adjusted EBITDA was $78.4 million, or 18.7% of revenue, versus $71.2 million, or 17.1%, a year earlier
- Full-year reported revenue guidance was lowered from $1.662 billion-$1.702 billion to $1.654 billion-$1.695 billion; 2026 adjusted EPS guidance of $2.40-$2.50 was reaffirmed
- Q3 2026 guidance calls for reported revenue of $410 million to $425 million and adjusted EPS of $0.53 to $0.61
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.